PLIANT THERAPEUTICS, INC. — Form 10-Q
Filed August 11, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 8/100
What the filing says
Bernard Coulie (CEO) and Keith Cummings (CFO) certified the June 30, 2026 Form 10-Q on August 11, 2026. Both officers attest that the report contains no untrue material statements, financial statements fairly present the company's condition and operations, and disclosure controls and internal controls over financial reporting are effective. No material weaknesses, significant deficiencies, or fraud involving management are reported.
Why this rating
Routine SOX 302/906 certifications; no substantive business change or financial disclosure revealed in these exhibits alone. Standard quarterly compliance.
See more from August 11, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.